Akero Therapeutics, Inc. (AKRO)
| Market Cap | 1.43B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -179.27M |
| Shares Out | 69.15M |
| EPS (ttm) | -3.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 553,780 |
| Open | 19.66 |
| Previous Close | 19.65 |
| Day's Range | 19.46 - 21.46 |
| 52-Week Range | 11.25 - 58.38 |
| Beta | -0.29 |
| Analysts | Strong Buy |
| Price Target | 43.88 (+112.8%) |
| Earnings Date | May 10, 2024 |
About AKRO
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manuf... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $43.88, which is an increase of 112.80% from the latest price.
News
Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Cal...
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
NEW ORLEANS , May 10, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 25, 20...
AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Akero Therapeutics, Inc.
SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP is Investigating Allegations Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Trial Drug Candidate.
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
RADNOR, Pa. , May 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United State...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of invest...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and ...
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pur...
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK , May 8, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed again...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
NEW YORK , May 7, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 ...
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.
Upcoming Lead Plaintiff Deadline is June 25, 2024 NEW YORK , May 7, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class acti...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purch...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Akero Therapeutics, Inc. (“Akero” or the “Compa...
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
NEW ORLEANS , May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Akero Therapeutic...
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP Investigates Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Drug Candidate.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) investors concerning the Compa...
AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Akero business and prospects, resulting in its stock trading at inflated prices.
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) on behalf of investors concerning the Co...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" o...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
LOS ANGELES , May 1, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or...
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
RADNOR, Pa. , May 1, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United State...
AKRO INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -AKRO
NEW YORK , April 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Akero Therap...
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
NEW YORK , April 29, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors ...